Established 2016|Australia's longest-standing research supplier|Trusted by 4,000+ researchers & labs|Batch-tested · Fast AU-wide dispatch
VCP Australia
Sign In
Coenzymes & NAD Precursors

NMN (Nicotinamide Mononucleotide)

A direct biosynthetic precursor of NAD+ studied in pre-clinical models of ageing and metabolic decline.

Education Hub

Pre-clinical mechanism

Animal models show oral NMN raises tissue NAD+ levels through Slc12a8 and NRK pathways, with downstream effects on insulin sensitivity, vascular function and exercise capacity.

Key pre-clinical findings

  • Aged mouse skeletal muscle: improved insulin sensitivity and mitochondrial gene expression after 12 months of NMN supplementation (Mills et al., 2016).

Primary literature

Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice

Mills KF, Yoshida S, Stein LR, et al. · Cell Metabolism · 2016

Research and educational use only. This page summarises publicly available pre-clinical literature for educational and scientific reference. It is not medical, clinical, dosing or therapeutic advice. Nothing on this page implies that any VCP Australia product is approved, certified, safe, effective, suitable for a particular purpose, or intended for human or animal consumption.

Research-Use Notice

Products displayed on this website may be intended for laboratory, analytical or research purposes only where applicable. They are not intended to diagnose, treat, cure or prevent any disease. They are not supplied for human or animal consumption unless expressly stated and lawfully permitted. Customers are responsible for understanding and complying with all applicable laws and regulations. Product information is provided for informational purposes only and does not constitute medical advice.

Read Full Disclaimer